Keystone FinancialIf you attended KeyStone’s Fall 2023 Live Webinars and became a client to our Small-Cap Research, below we provide Quick Updates on the first two Canadian Small-Cap Recommendations new clients received following the event. For clients, our initial Focus BUY recommendation following the 2023 Live Webinars was Cipher Pharmaceuticals (CPH:TSX).
Quick Update:
Cipher Pharmaceuticals (CPH:TSX)
Recommended: August 28, 2023, at $3.89
Today’s Price: $14.62
Gain: 275.83%
Cipher (CPH:TSX) is a unique specialty pharmaceutical Small-Cap Stock that is profitable, growing organically & via acquisitions, with a strong cash rich (originally 45%+ of its value in cash & no debt) balance sheet. The stock recently made a transformational acquisition and continues to report solid financial results driving it to new highs. Cipher is a recent excellent example of how research can produce strong gains for clients.
Cipher has now gained over 275% in less than one year. The huge gains are not driven by hype but powered by strong earnings and a transformational acquisition made primarily from cash on hand without diluting existing shareholders.
Quick Update:
VitalHub (VHI:TSX)
Recommended: November 2023, at $3.24
Today’s Price: $8.46
Gain: 161.11%
KeyStone’s second Small-Cap BUY recommendation to clients following our 2023 Webinars, was VitalHub (VHI:TSX), a small-cap Canadian healthcare software company, at a price of $3.24. We had followed VitalHub and interviewed management for years, but were monitoring the stock for an attractive entry point. Just 9 months after our initial recommendation the stock is 161.11% to $8.46, driven by strong cash flow generation, a significant acquisition and a cash rich balance sheet.